Acer Therapeutics Inc (ACER)
Market Open
20 Nov, 20:59
NASDAQ (CM) NASDAQ (CM) Primary $
0. 66
-0.14
-17.949%
$
- Market Cap
- P/E Ratio
- Div Yield
574,675 Volume
- Eps
$ 0.8
Previous Close Want to track ACER and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
ACER trading today lower at $0.66, a decrease of -17.949% from yesterday's close, completing a monthly increase of 0% or $0.66. Over the past 12 months, ACER stock gained 0%.
ACER is not paying dividends to its shareholders.
The last earnings report, released on Aug 12, 2024, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.03%, based on the last three reports.
Acer Therapeutics Inc has completed 5 stock splits, with the recent split occurring on Sep 21, 2017.
The company's stock is traded on one exchange.
ACER Chart
Acer Therapeutics Inc (ACER) FAQ
What is the stock price today?
The current price is $0.66.
On which exchange is it traded?
Acer Therapeutics Inc is listed on NASDAQ (CM).
What is its stock symbol?
The ticker symbol is ACER.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has Acer Therapeutics Inc ever had a stock split?
Acer Therapeutics Inc had 5 splits and the recent split was on Sep 21, 2017.
Acer Therapeutics Inc Profile
| Biotechnology Industry | Healthcare Sector | Christopher Schelling CEO | NASDAQ (CM) Exchange | 00444P108 CUSIP |
| US Country | 30 Employees | - Last Dividend | 29 Sep 2015 Last Split | - IPO Date |
Acer Therapeutics Inc. is a pharmaceutical company dedicated to acquiring, developing, and commercializing treatments for severe rare and life-threatening conditions. Its clinical-stage pipeline features four key candidates: EDSIVO, for vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a sodium phenylbutyrate formulation addressing inborn errors of metabolism such as urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant), designed to manage induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy showing promise against various infectious diseases, including COVID-19. The company also collaborates with the National Center for Advancing Translational Sciences (NCATS) on developing emetine hydrochloride for COVID-19 and holds worldwide licensing rights for osanetant, a selective NK3 receptor antagonist, through an agreement with Sanofi. Established in 1991, Acer Therapeutics Inc. is headquartered in Newton, Massachusetts.
Contact Information
Address: One Gateway Center
Phone: 844 902 6100
Website: https://www.acertx.com
